Literature DB >> 27732130

Hepatitis C: how has France limited the expenses related to new treatments?

Anne-Laure Mouterde1, François Bocquet1,2,3, Isabelle Fusier1, Pascal Paubel1,2,3.   

Abstract

Keywords:  HCV treatment; direct-acting antivirals; equity; financing mechanism; hepatitis C; sustainability; viral hepatitis

Mesh：

Substances：

Year:  2016        PMID： 27732130     DOI： 10.1080/14737167.2016.1247696

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN： 1473-7167            Impact factor:   2.217


× No keyword cloud information.
  1 in total

1.  Rapid and large-scale implementation of HCV treatment advances in France, 2007-2015.

Authors:  Cécile Brouard; Marjorie Boussac-Zarebska; Christine Silvain; Julien Durand; Victor de Lédinghen; Josiane Pillonel; Elisabeth Delarocque-Astagneau
Journal:  BMC Infect Dis       Date:  2017-12-20       Impact factor: 3.090
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.